Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Decreases By 53.1%

OnKure Therapeutics, Inc. (NASDAQ:OKUR) was the recipient of a large decline in short interest in December. As of December 31st, there was short interest totaling 24,394 shares, a decline of 53.1% from the December 15th total of 51,986 shares. Based on an average daily volume of 103,510 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.2% of the company’s stock are sold short. Currently, 0.2% of the company’s stock are sold short. Based on an average daily volume of 103,510 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on OKUR shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of OnKure Therapeutics in a research note on Monday, December 22nd. Wall Street Zen raised shares of OnKure Therapeutics to a “sell” rating in a research report on Saturday, November 1st. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $32.00.

Hedge Funds Weigh In On OnKure Therapeutics

Several hedge funds have recently made changes to their positions in the company. Shay Capital LLC grew its stake in OnKure Therapeutics by 17.4% during the 3rd quarter. Shay Capital LLC now owns 917,934 shares of the company’s stock worth $2,524,000 after buying an additional 135,888 shares during the last quarter. Prosight Management LP boosted its holdings in shares of OnKure Therapeutics by 67.8% in the third quarter. Prosight Management LP now owns 267,959 shares of the company’s stock valued at $737,000 after acquiring an additional 108,267 shares during the period. GSA Capital Partners LLP boosted its holdings in shares of OnKure Therapeutics by 172.1% in the third quarter. GSA Capital Partners LLP now owns 59,224 shares of the company’s stock valued at $163,000 after acquiring an additional 37,459 shares during the period. Rangeley Capital LLC purchased a new position in shares of OnKure Therapeutics during the second quarter worth approximately $71,000. Finally, Acorn Capital Advisors LLC increased its holdings in shares of OnKure Therapeutics by 97.2% in the 2nd quarter. Acorn Capital Advisors LLC now owns 2,839,674 shares of the company’s stock valued at $6,787,000 after acquiring an additional 1,400,000 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

OnKure Therapeutics Stock Down 0.3%

OnKure Therapeutics stock traded down $0.01 during mid-day trading on Friday, hitting $3.00. The company had a trading volume of 24,521 shares, compared to its average volume of 83,948. OnKure Therapeutics has a 1 year low of $1.70 and a 1 year high of $6.48. The business has a fifty day moving average of $2.96 and a 200 day moving average of $2.76. The stock has a market cap of $40.65 million, a price-to-earnings ratio of -0.63 and a beta of 0.47.

OnKure Therapeutics (NASDAQ:OKUR) last issued its earnings results on Thursday, November 6th. The company reported ($1.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.11. Equities analysts anticipate that OnKure Therapeutics will post -4.05 earnings per share for the current year.

About OnKure Therapeutics

OnKure Therapeutics, Inc (NASDAQ: OKUR) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology and autoimmune diseases. Headquartered in Westlake Village, California, OnKure is advancing small molecule drug candidates designed to modulate key signaling pathways implicated in cancer cell growth and immune system function.

The company’s lead oncology asset, OKI-179, is an orally available histone deacetylase (HDAC) inhibitor being evaluated in Phase I and Phase II clinical studies for a range of solid tumors.